Réaction #135

ord-1aa2de1a9b014f58b717c720b31e4a66

Équation de réaction

Nc1c(Cl)cnc2c1OCO2
Nc1c(Cl)cnc2c1OCO2
O=C(Nc1cc(Cl)ccn1)C1CC1
O=C(Nc1cc(Cl)ccn1)C1
O=C(Nc1cc(Nc2c(Cl)cnc3c2OCO3)ccn1)C1CC1
O=C(Nc1cc(Nc2c(Cl)cn
Rendement 32.5%

Solvants

Conditions de réaction

Température
130°CELSIUS

Mode opératoire

2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine (0.190 mL, 1.27 mmol) was added to a mixture of N-(4-chloropyridin-2-yl)cyclopropanecarboxamide (100 mg, 0.51 mmol), 6-chloro-[1,3]dioxolo[4,5-b]pyridin-7-amine (105 mg, 0.61 mmol) and BIS(DIBENZYLIDENEACETONE)PALLADIUM(0) (26.3 mg, 0.05 mmol) and (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (29.4 mg, 0.05 mmol) in toluene (1 mL) in a microwave tube. The reaction was degased, purged with argon and heated to 130 °C over a period of 7 hours in an oil bath. The mixture was diluted with dichloromethane, washed with water (emulsion), with brine, dried over MgSO4 and concentrated. The crude product was purified by flash chromatography on silica gel eluting with 0 to 3% methanol in dichloromethane. The solvent was evaporated to dryness to afford N-(4-(6-chloro-[1,3]dioxolo[4,5-b]pyridin-7-ylamino)pyridin-2-yl)cyclopropanecarboxamide (55.0 mg, 32.5 %) as a yellow solid.

Source

750 AstraZeneca ELN dataset